


Corporate Data	
SmartmAb Josef-Schneider-Str. 2, Bau D15 97080 Würzburg Contact: ++(0)931-3182155 Knut.ohlsen@mail.uni-wuerzburg.de	
Core Team and Responsibilities	
<ul style="list-style-type: none"> • Dr. Knut Ohlsen, Designated business director • Dr. Udo Lorenz, Shareholder, head clinical studies • Dr. Antje Michel, Research and development • Dr. Karin Streker, Research and development 	
Technologies and Intellectual Properties	
<ul style="list-style-type: none"> • Development of monoclonal antibody therapy against Staphylococcus aureus • Mouse monoclonal antibodies showed efficiency in three animal models • Humanization of antibody in progress • GMP production planned for 2011 • Patent application May 2009 	
Business Model, Market Strategies, Competitors	
<ul style="list-style-type: none"> • Development of humanized antibodies against S. aureus and management of studies including preclinical development, clinical studies phase I and II • Search for strategic partners for clinical phase III studies • Development of immune therapeutics against other antibiotic resistant nosocomial pathogens e.g. S. epidermidis, enterococci, ESBL producing Gram-negative bacteria • Chance: increasing rates of antibiotic resistant pathogens • No vaccine or immunotherapy against Staphylococcus aureus on the market • Blockbuster market with sales potential of >2 Mrd Euros annually (based on Deutsche Bank market research 2009) • Main competitors: Nabi in cooperation with GSK, Biosynexus Inc., Merck and Intercell (vaccine) 	
Current Status	
<ul style="list-style-type: none"> • Basic research since 1999 • Formation of business team within the frame of BMBF "Exist" programme • Participation in business plan competitions of the network Nordbayern in 2009, team winner in phase 1 and phase 2, second prize in university founder prize competition of North Bavarian universities • Winner of GO-Bio competition of BMBF in autumn 2009 (up to 3. Mio. Euros) • Next steps: Humanization and preclinical development of antibodies, GMP production, preparation of application for clinical studies 	
Offers and Requests	
<ul style="list-style-type: none"> • Unique antibodies against Staphylococcus aureus • In house availability of several infection models • Search for strategic partners clinical studies • Search for financial partners 	